Wu, Hao
Estrella, Veronica
Beatty, Matthew
Abrahams, Dominique
El-Kenawi, Asmaa http://orcid.org/0000-0003-2039-2825
Russell, Shonagh http://orcid.org/0000-0003-1066-6132
Ibrahim-Hashim, Arig
Longo, Dario Livio http://orcid.org/0000-0002-6906-9925
Reshetnyak, Yana K.
Moshnikova, Anna
Andreev, Oleg A.
Luddy, Kimberly
Damaghi, Mehdi
Kodumudi, Krithika
Pillai, Smitha R. http://orcid.org/0000-0001-9718-5010
Enriquez-Navas, Pedro
Pilon-Thomas, Shari
Swietach, Pawel http://orcid.org/0000-0002-9945-9473
Gillies, Robert J. http://orcid.org/0000-0002-8888-7747
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Cancer Institute (R01 CA077575, U54 CA193489, P30 CA076292)
U.S. Department of Health & Human Services | NIH | National Cancer Institute
U.S. Department of Health & Human Services | NIH | National Cancer Institute
Fulbright Association (0001)
Article History
Received: 21 November 2019
Accepted: 13 July 2020
First Online: 17 August 2020
Competing interests
: R.J.G. has research support form Helix Biopharma, who makes acid pH targeting agents. These agents were not used in the current work. O.A.A. and Y.K.R. are founders of pHLIP, Inc. They have shares in the company, but the company did not fund any part of the work reported in this paper, which was carried out in their academic laboratories. No other authors report competing interests.